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Hiroshima, JapanBackground and Aims: Although advanced high-volume centers have reported good outcomes of colorectal
endoscopic submucosal dissection (ESD), a limited number of highly skilled experts in specialized institutions
performed these procedures. We undertook a retrospective multicenter survey, which included nonspecialized
hospitals, to investigate the clinical outcomes of colorectal ESD.
Methods: We recruited 1233 consecutive patients with 1259 colorectal tumors resected by ESD at 12 institutions.
We evaluated the en bloc resection rate, histologic complete resection rate, curative (R0) resection rate, adverse
events, and the long-term prognoses, including local recurrence, metachronous tumor development, and survival
rate.
Results: The en bloc, histologic complete, and R0 resection rates were 92.6%, 87.4%, and 83.7%, respectively.
The delayed bleeding, intraoperative perforation, and delayed perforation rates were 3.7%, 3.4%, and .4%, respec-
tively. The long-term outcomes analysis included 1091 patients (88.4%). Local recurrences occurred in 1.7%, and
metachronous tumors (>5 mm) developed in 11.0% of the patients. The 3- and 5-year overall survival rates were
95.1% and 92.3%, respectively. The number of colonic tumors, severe submucosal fibrosis, and en bloc resection
rates were significantly higher in the high-volume centers (Group H) than those in the low-volume centers
(Group L). The average tumor size in Group H was significantly larger than that in Group L.
Conclusions: Colorectal ESDs are feasible, have acceptable adverse event risks, and favorable long-term progno-
ses. (Clinical trial registration number: UMIN000016197.) (Gastrointest Endosc 2018;87:714-22.)ns: ESD, endoscopic submucosal dissection; JSCCR, the Japa-
y for Cancer of the Colon and Rectum; LST-G, laterally
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Boda et al Clinical outcomes of colorectal ESDIn Japan, colorectal endoscopic submucosal dissection
(ESD) received health insurance approval in April 2012,
and it is a reliable method for treating superficial colorectal
tumors. Indeed, it is now possible to resect large tumors
completely and to evaluate tumors pathologically in detail
using ESD.1-18 Because the morbidity associated with colon
carcinomas is rising in Japan,19 the number of ESDs for
colorectal tumors will continue to increase.
Colorectal ESD is technically more difficult and requires
more experience than gastric ESD because of difficulties
associated with endoscope control and the anatomic fea-
tures of the colorectal region, including the presence of
folds, bending of the intestinal tract, and the thinness of
the intestinal wall. Although advanced high-volume centers
have reported good outcomes from colorectal
ESD,8,11,13,20-24 the procedures were performed by a
limited number of highly skilled experts. Few reports are
available that describe the outcomes from colorectal ESD
performed by less-experienced endoscopists at institutions
that have recently introduced colorectal ESD, and the cur-
rent status regarding colorectal ESD at a regional level has
not been disclosed. The aim of this study was to undertake
a retrospective multicenter survey, which included nonspe-
cialized hospitals in the Hiroshima area, to investigate the
clinical outcomes of colorectal ESD.METHODS
Patients
This retrospective analysis was conducted at 12 hospitals,
comprising 1 academic center and 11 community hospitals
(Hiroshima GI Endoscopy Research Group), in the Hirosh-
ima area that had different levels of experience in colorectal
ESD. Between January 2008 and March 2014 we recruited
1233 consecutive patients, comprising 748 men and 485
women with a mean age of 69 years (standard deviation
[SD], 23),whohad 1259 colorectal tumors thatwere resected
using ESD. Table 1 summarizes the clinical characteristics of
the patients and the tumors that were treated by ESD at
each institution. All data were processed centrally.
The indications for ESDweredefinedusing the criteria pro-
posed by the Japan Gastroenterological Endoscopy Society25
and the Japanese Society of Gastroenterology.26 ESD was
indicated for tumors that required en bloc resection and for
which en bloc resection using snare EMR would have been
difficult,27 which included laterally spreading tumors of the
nongranular type (LST-NG), particularly, the pseudo-
depressed type; tumors with a type VI pit pattern; carcinomas
with submucosal shallow invasions <1000 mm; large
depressed tumors; and large elevated tumors that were prob-
ablymalignant, including large nodular lesions such as laterally
spreading tumors of the granular type (LST-G). In addition,
ESD was indicated for intramucosal tumors with fibrosis
caused by biopsy sampling or peristalsis, local residual early-
stage carcinomas that developed after endoscopic resection,www.giejournal.organd sporadic localized tumors associated with chronic intesti-
nal inflammation conditions, including ulcerative colitis.
The study was performed in accordancewith theDeclara-
tion of Helsinki. All patients were informed of the risks and
benefits of ESD, and each patient provided written informed
consent for the procedure to be performed. None of the pa-
tients refused ESD for colorectal tumors during the study
period. The clinical trial number for this study is
UMIN000016197 (Institutional Review Board registration
date: January 14, 2015).
ESD procedure
The ESD procedures were performed using ESD devices
and involved the use of a dual knife (Olympus Medical Sys-
tems Corp, Tokyo, Japan), flex knife (Olympus Medical Sys-
tems Corp), hook knife (Olympus Medical Systems Corp),
IT knife (Olympus Medical Systems Corp), flush knife (Fu-
jifilm Corporation, Tokyo, Japan), and an SB knife Jr (Sumi-
tomo Bakelite Co, Ltd, Tokyo, Japan), as appropriate, for
each tumor. After the injection of a 10% glycerin solution
and/or .4% sodium hyaluronate (Muco Up; Johnson &
Johnson, New Brunswick, NJ) into the submucosal layer,
a circumferential incision was made using a single ESD
knife, and the ESD was performed using 1 or 2 ESD knives.
Histologic assessment
All specimens were fixed in 10% formalin, cut into 2-mm
sections, and examined microscopically. A histologic com-
plete resection was defined as a histopathologically com-
plete en bloc resection with negative tumor margins. A
curative (R0) resection was determined using the Japanese
Society for Cancer of the Colon and Rectum (JSCCR)
guideline criteria, which involved satisfying all 4 of the
following characteristics: a well/moderately differentiated
or papillary carcinoma, no vascular invasion, a submucosal
invasion depth <1000 mm, and grade 1 budding.19
The inclusion of an additional colectomy with lymph
node dissection was considered based on the guidelines
that were current at the time.28,29 In this study we retrospec-
tively reassessed all tumors using the 2016 JSCCR guidelines.
Variable evaluation
We evaluated the clinicopathologic characteristics of the
patients and tumors, procedure times, en bloc resection
rate, histologic complete resection rate, R0 resection
rate, adverse events, and long-term prognoses, including
local recurrences, metachronous tumor development,
and the survival rate. Poor scope operability was defined
as situations in which paradoxical movement of the endo-
scope, poor control with adhesions, and lesion motion
with heart beats or breathing occurred, as reported previ-
ously.30 Endoscopically, the degree of submucosal fibrosis
was classified as no fibrosis, mild fibrosis, and severe
fibrosis. Delayed bleeding was defined as a reduction in
the hemoglobin level 2 g/dL compared with the
preoperative level, apparent bleeding, or massiveVolume 87, No. 3 : 2018 GASTROINTESTINAL ENDOSCOPY 715
TABLE 1. Clinical characteristics of patients and tumors treated by endoscopic submucosal dissection at each institution
Variable
Institution
1 2 3 4 5 6 7 8 9 10 11 12
Number of patients 548 164 164 126 80 65 44 23 5 5 5 4
Number of tumors 562 169 167 126 84 65 44 23 5 5 5 4
Operator’s experience in
colonoscopy, y, mean (SD)
29 (2) 19 (2) 16 (4) 14 (2) 21 (4) 17 (6) 11 (3) 11 (2) 20 (1) 16 (1) 12 (2) 12 (.5)
Sex, male/female 332/216 104/60 98/66 72/54 48/32 38/27 28/16 15/8 4/1 2/3 4/1 3/1
Age, y, mean (SD) 67 (11) 68 (10) 69 (10) 69 (12) 68 (9) 70 (10) 71 (9) 67 (9) 74 (5) 69 (17) 66 (9) 59 (12)
Tumor location
Right side of colon, n 236 56 93 37 26 26 13 5 0 1 1 1
Left side of colon, n 118 40 20 37 18 8 12 6 3 0 0 2
Rectum, n 208 73 54 52 40 31 19 12 2 4 4 1
Growth type
LST-G, n 271 83 77 57 27 52 19 14 1 3 2 1
LST-NG, n 214 34 70 45 31 9 20 8 4 1 1 3
Polypoid, n 77 52 20 24 26 4 5 1 0 1 2 0
Tumor size, mm, mean (SD) 36 (19) 34 (17) 30 (14) 26 (18) 29 (13) 29 (11) 23 (11) 36 (19) 19 (5) 26 (6) 22 (7) 25 (5)
Experience of taking part in the
previous multicenter study
Yes No No No No No No No No No No No
SD, Standard deviation; LST-G, laterally spreading tumor of the granular type; LST-NG, laterally spreading tumor of the nongranular type.
Clinical outcomes of colorectal ESD Boda et almelena.31 We categorized the 12 participating hospitals
into high-volume centers (Group H) or low-volume cen-
ters (Group L), based on the number of ESDs performed
during the study period (100 tumors/6 years) in accor-
dance with a previous report.11 We compared the groups
with respect to the clinicopathologic characteristics of
the tumors and the clinical outcomes of ESD.
Surveillance after ESD
At 1 year after ESD, follow-up colonoscopies were per-
formed on patients who had undergone histologically com-
plete resections of high-grade dysplasias and T1 carcinomas
that had met the curative criteria. For the patients whose re-
sections of their high-grade dysplasias were piecemeal and
whose tumors had histologically positive horizontal mar-
gins, follow-up colonoscopies were performed at 3 to 6
months after ESD, and further colonoscopies were per-
formed 1 year later. For the patients who had undergone
ESD for T1 carcinomas that had notmet the curative criteria,
blood tests, including the carcinoembryonic antigen level,
and CT of the abdomen and pelvis were performed every
6 months postoperatively for the first 3 years and every 12
months thereafter, and follow-up colonoscopies were per-
formed every year. We sent a questionnaire to those patients
who did not have any follow-up medical records at our insti-
tution or at our partner centers to investigate the long-term
outcomes.
Statistical analyses
The Student t test and the Mann-Whitney U test were
used to compare the continuous variables, and the Pearson716 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 3 : 2018c2 test and the Fisher exact probability test were used to
compare the categorical variables. The Kaplan-Meier
method was used for the survival analyses and to deter-
mine the proportion of the patients with metachronous tu-
mors. P < .05 were considered statistically significant. All
statistical analyses were performed using JMP software,
version 10 (SAS Institute Inc., Cary, NC).RESULTS
Clinicopathologic characteristics of the cases
Table 2 shows the clinicopathologic characteristics of
tumors and patients. Regarding the locations of the
tumors, 495 tumors (39.3%) were located in the right
side of the colon, 264 tumors (21.0%) were located in
the left side of the colon, and 500 tumors (39.7%) were
located in the rectum. There were 607 LST-G (48.2%),
440 LST-NG (35.0%), and 212 polypoid tumors (16.8%).
Histologically, 667 tumors (53.0%) were high-grade dyspla-
sias, 104 tumors (8.3%) were superficial submucosal inva-
sive carcinomas (<1000 mm), 153 tumors (12.1%) were
deep submucosal invasive carcinomas (1000 mm), and
335 tumors (26.6%) were low-grade dysplasias.
Short-term outcomes
The short-term outcomes of colorectal ESD are shown in
Table 3. The mean (SD) tumor size was 33 (17) mm (range,
10-138), and the mean (SD) procedure time was 92 (66)
minutes (range, 5-660). The en bloc resection, histologic
complete resection, and R0 resection rates were 92.6%www.giejournal.org
TABLE 2. Clinicopathologic characteristics of patients and tumors treated by endoscopic submucosal dissection at the high- and low-volume
centers
Variable Total
Group
P valueHigh-volume centers Low-volume centers
Number of patients 1233 1002 231
Number of tumors 1259 1024 235
Sex
Male 748 (60.7) 606 (60.5) 142 (61.5) NS
Female 485 (39.3) 396 (39.5) 89 (38.5)
Age, y, mean (SD) 69 (23) 69 (25) 69 (10) NS
Tumor location
Right side of colon 495 (39.3) 422 (41.2) 73 (31.0) <.05
Left side of colon 264 (21.0) 215 (21.0) 49 (20.9)
Rectum 500 (39.7) 387 (37.8) 113 (48.1)
Growth type
LST-G 607 (48.2) 488 (47.7) 119 (50.6) NS
LST-NG 440 (35.0) 363 (35.4) 77 (32.8)
Polypoid 212 (16.8) 173 (16.9) 39 (16.6)
Use of anticoagulants and/or antiplatelet therapy
Yes 147 (11.7) 110 (10.7) 37 (15.7) NS
No 1112 (88.3) 914 (89.3) 198 (84.3)
Submucosal fibrosis
None or mild 941 (74.7) 747 (72.9) 194 (82.6) <.05
Severe 318 (25.3) 277 (27.1) 41 (17.4)
Histology
Low-grade dysplasia 335 (26.6) 260 (25.4) 75 (31.9) <.05
High-grade dysplasia 667 (53.0) 542 (52.9) 125 (53.2)
T1 carcinoma (<1000 mm) 104 (8.3) 88 (8.6) 16 (6.8)
T1 carcinoma (1000 mm) 153 (12.1) 134 (13.1) 19 (8.1)
Values are number of cases with percents in parentheses, unless otherwise noted.
NS, Not significant; SD, standard deviation; LST-G, laterally spreading tumor of the granular type; LST-NG, laterally spreading tumor of the non-granular type.
Boda et al Clinical outcomes of colorectal ESD(1166/1259), 87.4% (1100/1259), and 83.7% (1054/1259),
respectively. Regarding the non-R0 resected tumors, 134
tumors (10.6%) underwent additional surgical resection
and 71 tumors (5.6%) were followed without surgery
because either the patients refused to undergo additional
surgical resection and/or they had severe concomitant dis-
eases. Delayed bleeding after ESD occurred in 46 patients
(3.7%). Intraoperative perforations occurred in 43 patients
(3.4%), and 6 of these patients (.5%) required surgery.
Delayed perforations occurred in 5 patients (.4%), and 4
of these patients (.3%) required surgery.
Long-term outcomes
To evaluate the long-term outcomes we excluded 11 pa-
tients with 11 tumors whose ESD procedures could not
continue because of perforations (5 patients, 5 tumors),
submucosal severe fibrosis (4 patients, 4 tumors), and in-
traoperative bleeding (2 patients, 2 tumors). We excluded
an additional 131 patients who were lost to follow-upwww.giejournal.orgwithin 6 months. Hence, 1091 patients with 1117 tumors
(88.7%) were included in the analysis of the long-term out-
comes, and the mean (SD) follow-up duration was 36 (21)
months (range, 6-90) (Fig. 1).
Figure 2 presents the survival curves. The 3- and 5-year
overall survival rates were 95.1% and 92.3%, respectively.
Both the 3- and 5-year disease-specific survival rates were
99.6%. Of 1091 patients, 45 patients (4.1%) died because
of concomitant diseases and 2 patients (.2%) died because
of their colorectal carcinomas. Table 4 summarizes the
characteristics of the patients who died because of their
colorectal carcinomas.
To evaluate metachronous tumor development, we
excluded 209 patients who did not undergo colonoscopy
after ESD, and we assessed 882 patients with 904 tumors
(Fig. 1). The cumulative incidence rate for metachronous
tumor development is shown in Figure 3. The mean (SD)
follow-up duration was 30 (19) months (range, 6-90). Meta-
chronous tumors (>5 mm) developed in 11.0% of patientsVolume 87, No. 3 : 2018 GASTROINTESTINAL ENDOSCOPY 717
TABLE 3. Outcomes of endoscopic submucosal dissection for colorectal tumors at the high- and low-volume centers
Variable Total
Group
P valueHigh-volume centers Low-volume centers
Tumor size, mm, mean (SD) 33 (17) 40 (18) 28 (13) <.01
Scope operability
Good 873 (69.3) 712 (69.5) 161 (68.5) NS
Poor 386 (30.7) 312 (30.5) 74 (31.5)
Procedure time, min, mean (SD) 92 (66) 92 (65) 96 (67) NS
Resection status
En bloc 1166 (92.6) 959 (93.7) 207 (88.1) <.05
Piecemeal 82 (6.5) 58 (5.7) 24 (10.2)
Discontinued procedure 11 (0.9) 7 (0.6) 4 (1.7)
Histologic complete resection
Complete 1100 (87.4) 898 (87.7) 202 (86.0) NS
Incomplete 159 (12.6) 126 (12.3) 33 (14.0)
Endoscopic curability
R0 resection 1054 (83.7) 844 (82.4) 210 (89.4) <.05
Non-R0 resection 205 (16.3) 180 (17.6) 25 (10.6)
Follow-up 71 (5.6) 66 (6.5) 9 (3.8)
Additional surgical resection 134 (10.6) 114 (11.1) 16 (6.8)
Adverse events
Delayed bleeding 46 (3.7) 38 (3.7) 8 (3.4) NS
Intraoperative perforation 43 (3.4) 36 (3.5) 7 (3.0)
Required surgery 6 (.5) 5 (0.5) 1 (0.4)
Delayed perforation 5 (.4) 5 (0.5) 0 (0)
Required surgery 4 (.3) 4 (0.4) 0 (0)
Values are number of cases with percents in parentheses, unless otherwise noted.
SD, Standard deviation; NS, not significant.
Clinical outcomes of colorectal ESD Boda et al(97/882), and high-grade dysplasias and T1 carcinomas
developed in 1.1% of patients (10/882).
To evaluate local tumor recurrence, we excluded 94
tumors that underwent additional surgery, and we investi-
gated 810 tumors. Local recurrences were observed in
1.7% of the tumors (14/810). The characteristics of these
tumors are shown in Table 5.
Histologically, 5 primary tumors were low-grade dyspla-
sias, 8 were high-grade dysplasias, and 1 was a T1 carci-
noma. Five of these tumors were resected using the
piecemeal method, and the local recurrence rate was
significantly higher after piecemeal resections compared
with that for en bloc resections (P < .01). The times to
recurrence ranged from 6 to 53 months. Thirteen tumors
underwent additional endoscopic resections, and 1 tumor
required surgery.
Comparisons of Groups H and L with respect to
the clinicopathologic characteristics of tumors
and procedural outcomes
Table2 summarizes the clinicopathologic characteristics of
patients and tumors treated at the hospitals in Groups H and718 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 3 : 2018L. The hospitals in Group H treated 1002 patients with 1024
tumors and those in Group L treated 231 patients with 235
tumors. The proportion of rectal tumors in Group L (48.1%)
was significantly higher than that in Group H (37.8%; P <
.05). The severe submucosal fibrosis rate was significantly
higher in Group H (27.1%) compared with that in Group L
(17.4%; P < .05). The proportion of histologically verified
T1 carcinomas (1000 mm) in Group H (13.1%) was
significantly higher than that in Group L (8.1%; P < .05).
There were no significant differences between the groups
in relation to the sex ratio, the average age of the patients,
the tumor growth types, and the ratios of the use of
anticoagulants and/or antiplatelet therapy.
Table 3 summarizes the procedural outcomes associated
with ESD in Groups H and L. The mean (SD) tumor size in
Group H was 40 (18) mm (range, 10-138) and that in Group
L was 28 (13) (range, 10-85), a difference that was
significant (P < .01). The mean (SD) procedure times were
92 (65) minutes in Group H and 96 (67) minutes in Group
L, a difference that was not significant. The en bloc
resection rate was significantly higher in Group H (93.7%)
compared with that in Group L (88.1%; P < .05). Thewww.giejournal.org
ESD for colorectal tumors between  January 2008 and March 2014 at 12 hospitals
Number of enrolled patients = 1233; number of tumors = 1259                          
Procedure discontinued in 11 patients and 11 tumors,
because of 
  • Perforations: 5 patients, 5 tumors
  • Submucosal severe fibrosis:  4 patients,  4 tumors
  • Intraoperative bleeding: 2 patients,  2 tumors
 
1222 patients, 1248 tumors
Lost to follow-up (<6 months): 131 patients, 131 tumors
1091 patients, 1117 tumors (follow-up rate: 89%)
Average observation time: 36 months
Colonoscopy not performed: 209 patients, 213 tumors
882 patients, 904 tumors (follow-up rate: 72%)
Average observation time: 30 months
Figure 1. Flowchart of the enrolled patients and the tumors. ESD, Endoscopic submucosal dissection.
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Figure 2. Survival curve after endoscopic submucosal dissection for colo-
rectal tumors.
Boda et al Clinical outcomes of colorectal ESDhistologic complete resection rates were 87.7% in Group H
and 86.0% in Group L, a difference that was not significant.
Delayed bleeding occurred in 38 patients (3.7%) inGroup
H and in 8 patients (3.4%) in Group L. Intraoperative perfo-
rations occurred in 36 patients (3.5%) in Group H and in 7
patients (3.0%) in Group L. There were no significant differ-
ences between the groups in relation to the adverse events.DISCUSSION
Although several large case series studies have assessed
the outcomes from colorectal ESD, most of the analyseswww.giejournal.orgwere undertaken in high-volume centers until now. Naka-
jima et al22 conducted a prospective multicenter study at
medium- and high-volume specialized facilities and re-
ported that the endoscopic en bloc resection rate was
94.5%, the perforation rate was 1.6%, and the delayed
bleeding rate was 2.2%. Lee et al21 reported an overall
endoscopic en bloc resection rate of 97.5%, an R0
resection rate of 91.2%, and a perforation rate of 5.3%.
Repici et al32 undertook a systematic review of 22 studies
and reported a histologically verified per-lesion resection
rate of 88% and a per-lesion rate of 1% for surgical inter-
vention after adverse events associated with ESD.
Our data demonstrate the safety and efficacy of colo-
rectal ESD procedures carried out in the Hiroshima region.
The findings from the present study demonstrated almost
equivalent colorectal ESD statistics compared with those re-
ported previously, despite including low-volume centers. As
we reported previously,17 en bloc resection using ESD as a
total excisional biopsy sampling method for a clinical T1
colorectal carcinoma is an appropriate and effective
treatment, and we attempted ESD for clinical T1
carcinomas in some cases. As a result, 13.1% of the
tumors in Group H were deep submucosal invasive
carcinomas (1000 mm), which may explain why our R0
ESD resection rate was lower than that reported previously.
The en bloc resection rate in Group L was significantly
lower than that in Group H. Reports from studies that
investigated colorectal ESD learning curves have been pub-
lished.33,34 Yang et al34 evaluated the feasibility of surgeons
without experience in gastric ESD performing colorectal
ESD. They reported that ESD was attempted on 250
colorectal tumors by an endoscopist and that significantVolume 87, No. 3 : 2018 GASTROINTESTINAL ENDOSCOPY 719
TABLE 4. Characteristics of the patients who died of recurrent
colorectal carcinoma after endoscopic submucosal dissection
Variable Case 1 Case 2
Age, y 46 75
Sex Female Female
Characteristics of the lesion
Location Sigmoid colon Rb
Type IsþIIa IsþIIa
Histologic type wel>mod mod
Depth of submucosal
invasion, mm
1900 3500
Budding Grade 3 Grade 3
Vessel involvement ly0, v0 ly1, v1
Horizontal margin 0 0
Vertical margin 0 0
Additional surgical resection No No
Time to recurrence
from ESD, mo
41 13
Recurrence pattern Multiple liver
metastases
Multiple lung
metastases
Lymph node
metastasis
Lymph node
metastasis
Time to death from ESD, mo 71 19
Rb, Rectum below the peritoneal reflection; wel, well-differentiated adenocarcinoma;
mod, moderately differentiated adenocarcinoma; ly, lymphatic invasion, v, venous
invasion; ESD, endoscopic submucosal dissection.
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Figure 3. Metachronous tumor development after endoscopic submuco-
sal dissection for colorectal tumors.
Clinical outcomes of colorectal ESD Boda et alimprovements were observed in the success rate (from
72% to 94%; P Z .001) and the perforation rate (from
14% to 0%; P Z .003) as the surgeons gained experience.
Sato et al35 reported that severe fibrosis contributed to
incomplete resections and difficult colorectal ESD
procedures and that a larger tumor size was one of the
independent factors that contributed to the difficulty of
the colorectal ESD procedure. Furthermore, we reported
that poor endoscope operability and severe fibrosis were
significant independent predictors of perforation.30 Imai
et al36 reported that among less-experienced endoscopists,
colonic tumors were independent predictors of en bloc
resection failure and perforation. The data from the current
study showed that compared with Group L, the numbers of
tumors with severe submucosal fibrosis and colonic tumors
were higher in Group H. In addition, the average size of
the tumors was larger in Group H compared with that in
Group L. The tumors were allocated according to the level
of technical expertise within each facility. On the other
hand, Takeuchi et al37 reported that less-experienced endo-
scopists should perform colorectal ESD on LST-G initially,
because of the poor lifting that frequently occurs after
the submucosal injection during ESD for LST-NG and pro-
truding tumors. Furthermore, poor lifting after the submu-
cosal injection during colorectal ESD was the risk factor
that was most frequently associated with technical
difficulties and adverse events.37 There were no significant720 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 3 : 2018differences between Group H and Group L with respect
to the tumor growth types. Colorectal tumors should
be allocated more appropriately within the region by
considering the tumor growth types and endoscope
operability.
Some previously published articles describe the long-
term outcomes from ESD for colorectal tumors.20,38-40
We conducted a single-center retrospective study with a
median follow-up duration of 79 months and reported
that the 5-year overall survival and disease-specific survival
rates after colorectal ESD were 94.6% and 100%, respec-
tively.24 The data from the present study were almost
equivalent to those reported previously in relation to
long-term outcomes, despite including low-volume cen-
ters. Only 2 patients (.2%), who rejected additional surgical
resections, died as a consequence of their colorectal
carcinomas, and the prognosis for colorectal ESD was
good. The findings from another multicenter prospective
cohort study, which was a JSCCR research project,
showed that the local recurrence rate for colorectal
neoplasias 20 mm after ESD was 1.4% and that a signifi-
cant factor associated with local recurrence was a piece-
meal resection during ESD.23 However, our study
showed that local recurrences occurred in 6 of 810
tumors, even though en bloc resections and R0
resections had been achieved. It is important to detect
the minute amounts of residual tumor tissue that
surround the resected ulcer or ulcer bed after ESD, even
when an en bloc resection has been achieved, and to
evaluate and confirm the pathologic horizontal margin
carefully. Moreover, given that metachronous tumors
developed in 11.0% of the patients in our study, regional
surveillance is important to detect local recurrences and
metachronous tumors more rapidly after ESD.
This study has some limitations. First, this was a retro-
spective study based on clinical records. Second, we could
not follow all patients who underwent ESD; 11% of patients
were lost to follow-up within 6 months and 28% of patientswww.giejournal.org
TABLE 5. Characteristics of the cases who experienced local recurrence after endoscopic submucosal dissection for colorectal tumors
Case
no.
Age
(y) Sex
Characteristics of initial lesions Characteristics of local recurrent lesions
Location
Size
(mm)
Growth
type
Histologic
diagnosis
Resection
status HM VM
Time to
recurrence
(mo)
Size
(mm)
Growth
type
Histologic
diagnosis
Treatment
method
1 71 F Rb 35 LST-G Low-grade
dysplasia
Piecemeal þ  14 5 Is Low-grade
dysplasia
EMR
2 58 M Rb 55 LST-G Low-grade
dysplasia
En bloc   49 15 IIa Low-grade
dysplasia
ESD
3 52 F C 50 LST-G Low-grade
dysplasia
En bloc   7 2 Is Low-grade
dysplasia
Hot biopsy
4 70 M Rb 60 LST-G Low-grade
dysplasia
Piecemeal þ  10 10 Is Low-grade
dysplasia
EMR
5 70 M Rb 20 Polypoid High-grade
dysplasia
En bloc   20 10 IIa Low-grade
dysplasia
EMR
6 64 M S 25 LST-NG High-grade
dysplasia
Piecemeal þ  15 2 Is Low-grade
dysplasia
EMR
7 67 F C 20 Polypoid Low-grade
dysplasia
En bloc   53 4 IIa Low-grade
dysplasia
EMR
8 56 F A 25 LST-G High-grade
dysplasia
En bloc   7 10 Is Low-grade
dysplasia
EMR
9 74 M S 40 LST-G T1 carcinoma En bloc   17 10 SMT T1 carcinoma Surgery
10 52 M A 45 LST-G High-grade
dysplasia
Piecemeal þ þ 6 8 Is Low-grade
dysplasia
EMR
11 66 M A 50 LST-G High-grade
dysplasia
Piecemeal þ  6 3 Is  APC
12 63 M D 50 LST-G High-grade
dysplasia
En bloc þ  28 5 Is  APC
13 67 M Rb 100 LST-G High-grade
dysplasia
En bloc   6 10 Is Low-grade
dysplasia
EMR
14 65 M Ra 50 Polypoid High-grade
dysplasia
En bloc þ  17 5 Is Low-grade
dysplasia
EMR
HM, Horizontal margin; VM, vertical margin; LST-G, laterally spreading tumor of the granular type; Rb, rectum below the peritoneal reflection; C, cecum; A, ascending colon; D,
descending colon; S, sigmoid colon; Ra, rectum above the peritoneal reflection; LST-NG, laterally spreading tumor of the nongranular type; SMT, submucosal tumor; ESD,
endoscopic submucosal dissection; APC, argon plasma coagulation.
Boda et al Clinical outcomes of colorectal ESDdid not undergo surveillance colonoscopies after ESD.
Finally, this study included patients whose treatment did
not involve the use of the most advanced tools and devices
for colorectal ESD.
In summary, ESDs for colorectal tumors that presented
the greatest technical difficulties were performed at the
high-volume centers, and there were no significant differ-
ences between the high- and low-volume centers with
respect to the adverse events. The safety of colorectal
ESD in the Hiroshima area was maintained, likely because
the cases were allocated and the procedures were under-
taken in accordance with the skill level of each facility
and endoscopist.ACKNOWLEDGMENTS
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